Korea’s Yuhan joins Imperial College’s drug development funding program

2020.10.16 11:58:57

[Photo provided by Yuhan Corp.]이미지 확대

[Photo provided by Yuhan Corp.]

Yuhan Corp. has signed a memorandum of understanding to fund some proof of concept collaborative projects as an industry partner for London-based Imperial College’s ICiC (Imperial Confidence in Concept) program, the South Korean pharmaceutical firm announced on Friday.

The ICiC scheme aims to accelerate the transition from discovery science to the early stages of therapeutic development by funding preliminary translational work. The program, which has so far lasted for eight years, is pump-priming the translation of novel therapeutics, devices and diagnostics toward clinical testing with research grants from the British government, institutions and businesses.

The partnership program has yielded multiple achievements, Yuhan said.

The London-based public college is prestigious in research of medical biotechnology, focusing on translational research to realize social benefits. Major research fields include basic research in cancer, immunology, infection, fibrosis, and cognitive science, as well as the therapeutic development.

By Pulse

[ⓒ Pulse by Maeil Business Newspaper & mk.co.kr, All rights reserved]